Novo Nordisk's denecimig BLA delayed by manufacturing site remediation

Novo Nordisk has confirmed that the FDA's review of its Biologics License Application for denecimig, a bispecific antibody for haemophilia A, is running beyond its originally anticipated third-quarter 2026 decision date. The extension is attributable solely to ongoing remediation activities at the company's manufacturing facility, following a pre-licence inspection conducted after the September 2025 BLA submission.

The FDA has not identified deficiencies in the clinical efficacy or safety data underpinning the application, which was supported by the FRONTIER clinical programme. Novo said the delay has no bearing on its 2026 financial guidance, and the company is targeting a US launch in the first half of 2027, pending regulatory approval. The FDA has not provided a revised action date.

What went wrong at the facility

The Agency's pre-licence manufacturing inspection, a standard step before BLA approval, returned feedback that prompted remediation work. Novo said it is addressing the FDA's requests "as efficiently as possible" and that the issues do not affect any of its other marketed products. Mike Doustdar, president and chief executive of Novo, said the company's ambition is to "help make better care something [haemophilia A patients] can count on," framing the delay as a logistical rather than clinical setback.

Manufacturing readiness inspections have become an increasingly common chokepoint in biologics approvals. The FDA has applied heightened scrutiny to sterile fill-finish and biologic production facilities since a series of high-profile consent decrees and warning letters issued in the early 2020s. Companies with multiple manufacturing sites have generally fared better when a single facility encounters inspection-related delays, because they can propose alternative production arrangements. Novo has not indicated whether such an option is available for denecimig.

Competitive and regulatory context

Denecimig is a FVIIIa mimetic bispecific antibody that bridges factor IXa and factor X subcutaneously, mimicking the cofactor role of FVIII. The approach places it in direct competition with Roche's emicizumab (Hemlibra), the dominant non-replacement prophylactic therapy in haemophilia A, which has been approved in both inhibitor and non-inhibitor populations since 2018. Emicizumab set the benchmark for subcutaneous, infrequent dosing; denecimig's once-monthly dosing interval, if confirmed in routine clinical use, could be a meaningful differentiator for patients and payers.

Denecimig received a positive opinion from the EMA's Committee for Medicinal Products for Human Use on 17 September 2026 and is pending formal European marketing approval, giving Novo a potential near-term commercial foothold outside the US while it resolves the FDA's manufacturing requirements. Several other haemophilia A programmes, including gene therapy candidates from BioMarin and others, are also progressing through regulatory pathways, adding a degree of urgency to Novo's remediation timeline.

The haemophilia A treatment market has been reshaped significantly over the past decade by the shift from intravenous factor replacement to subcutaneous prophylaxis. Denecimig's approval would add a second major bispecific option to that landscape. How quickly Novo can satisfy the FDA's manufacturing requirements will determine whether its first-half 2027 launch target remains achievable.